All Photos(8)




Anti-SARS-CoV-1/2 NP Antibody, clone 1C7C7 ZooMAb® Mouse Monoclonal

enhanced validationgreener alternative

recombinant, expressed in HEK 293 cells

Sign Into View Organizational & Contract Pricing

NC, Nucleocapsid protein, Protein N.

biological source

mouse (recombinant)

Quality Level


expressed in HEK 293 cells



antibody form

purified antibody

antibody product type

primary antibodies


1C7C7, recombinant monoclonal

product line

ZooMAb® learn more



mol wt

calculated mol wt 45.63 kDa (SARS-CoV-2)
calculated mol wt 46.03 kDa (SARS-CoV)
observed mol wt ~46 kDa

species reactivity

SARS virus


antibody small pack of 25 μL

greener alternative product characteristics

Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.

enhanced validation

recombinant expression
Learn more about Antibody Enhanced Validation


affinity binding assay: suitable
flow cytometry: 1 μg/mL
immunocytochemistry: suitable
western blot: 1 μg/mL



UniProt accession no.

greener alternative category

shipped in


storage temp.


target post-translational modification


Gene Information

SARS coronavirus ... N(43740575)
SARS virus ... N(1489678)

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item








species reactivity

SARS virus

species reactivity

SARS virus

species reactivity

SARS virus

species reactivity

human, mouse


1C7C7, recombinant monoclonal


hu2B3E5, recombinant monoclonal


CR3022, recombinant monoclonal


1O17, monoclonal, recombinant monoclonal

Gene Information

SARS coronavirus ... N(43740575)
SARS virus ... N(1489678)

Gene Information

SARS coronavirus ... S(43740568)
SARS virus ... S(1489668)

Gene Information


Gene Information

human ... PIAS1(8554)

biological source

mouse (recombinant)

biological source

human (recombinant)

biological source


biological source

rabbit (recombinant)

Still not finding the right product?  

Give our Product Selector Tool a try.

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.


Clone 1C7C7 is a ZooMAb mouse recombinant antibody that specifically detects SARS-CoV-1/2 NP.


His-tagged full-length recombinant Nucleoprotein from SARS-CoV virus.


Anti-SARS-CoV-1/2 NP, clone 1C7C7 ZooMAb, Cat. No. ZMS1075, is a Mouse monoclonal antibody that detects nucleoprotein from SARS-CoV-1/2 and is tested for use in Affinity Binding Assay, Flow Cytometry, Immunocytochemistry, and Western Blotting.
Flow Cytometry Analysis: 1 mg /ml from a representative lot detected SARS-CoV-1/2 NP in Transfected 293expi cells (Courtesy of Dr Thomas Moran, Center for Therapeutic Antibody Development).

Immunocytochemistry Analysis: 1 μg/mL from a representative lot detected SARS-CoV-1/2 NP in Vero E6 cells infected with SARs-CoV-2 (Courtesy of Dr Ana Fernandez-Sesma Laboratory, Icahn School of Medicine at Mount Sinai (ISMMS), New York).

Western Blotting Analysis: A 1:5,000 dilution of this antibody detected SARS-CoV-1/2 NP in lysate from A549 cells infected with SARS-CoV-2 (Courtesy of Jeff Johnson Laboratory, Icahn School of Medicine at Mount Sinai (ISMMS).

Affinity Binding Assay: This antibody bound recombinant nucleoprotein from SARS-CoV-1/2 with a KD of 4.4 x 10-7 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Target description

Nucleoprotein (UniProt: P59595/P0DTC9; also known as Nucleocapsid protein, NC, Protein N) is encoded by the N gene (Gene ID: 1489678) in Human SARS coronavirus. The SARS-CoV-2 (COVID-19 causing virus) is a positive-strand RNA virus that causes severe respiratory syndrome in human. The mature SARS-CoV-2 contains 4 structural proteins: Envelope (E), Membrane (M), Nucleocapsid (N), and the Spike protein (S). Nucleoprotein of SARS-CoV and SARS-CoV-2 is a homooligomeric protein that packages the positive strand viral genome RNA into helical ribonucleocapsid and plays a role in virion assembly through its interactions with the viral genome and membrane protein M. It plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. The RNA binding region of SARS-CoV and SARS-CoV-2 is localized to amino acids 42-187 and 41-186, respectively. Lack of cysteine is one of the common features in nucleoprotein from different coronaviruses. The complete N protein of SARS-CoV and COV-2 is a highly basic with positive net charges and high pI (10.11). Its N-terminal region is more basic with positive charge, while the C-terminal region is acidic with negative charge. The middle region of nucleoprotein displays relatively higher hydrophobicity and the two termini display greater hydrophilicity. Nucleoprotein can undergo phosphorylation at multiple serines by GSK-3, CKII, Akt, CDKs, and Polo-like kinases. Some of these phosphorylation events are essential for RNA binding, oligomerization and localization to nucleoli. Phosphorylation is also required for recruitment of host RNA helicase DDX1 (DEAD-Box Helicase 1) that facilitates template readthrough and enables longer subgenomic mRNA synthesis. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Physical form

Purified mouse monoclonal antibody IgG2a in buffer containing PBS, 5% Trehalose without preservatives


300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Data presented is the available current product information and provided as-is. These products have not been tested or verified in any additional applications, sample types, including any clinical use. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested applications stated herein and conditions presented in our product information and is not extended to publications.

Storage Class

11 - Combustible Solids




Not applicable


Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).


Product Number
Pack Size/Quantity

Additional examples:





enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Ana S Gonzalez-Reiche et al.
Nature communications, 14(1), 3235-3235 (2023-06-04)
Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been reported in immune-compromised individuals and people undergoing immune-modulatory treatments. Although intrahost evolution has been documented, direct evidence of subsequent transmission and continued stepwise adaptation is lacking. Here we describe
Mauro Pavan et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 187, 106489-106489 (2023-06-14)
Despite several vaccines that are currently approved for human use to control the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is an urgent medical need for therapeutic and prophylactic options. SARS-CoV-2 binding and entry in human
Jun-Gyu Park et al.
Journal of virological methods, 287, 113995-113995 (2020-10-18)
Towards the end of 2019, a novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), genetically similar to severe acute respiratory syndrome coronavirus (SARS-CoV), emerged in Wuhan, Hubei province of China, and has been responsible for coronavirus disease 2019
J Andrew Duty et al.
Med (New York, N.Y.), 3(10), 705-721 (2022-09-01)
The continual emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern, in particular the newly emerged Omicron (B.1.1.529) variant and its BA.X lineages, has rendered ineffective a number of previously FDA emergency use authorized SARS-CoV-2 neutralizing antibody
Caleb D Swaim et al.
iScience, 24(10), 103213-103213 (2021-10-12)
The emergence of SARS-CoV-2 has led to a global health crisis that, in addition to vaccines and immunomodulatory therapies, calls for the identification of antiviral therapeutics. The papain-like protease (PLpro) activity of nsp3 is an attractive drug target as it

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service